SPXC, MACD Histogram just turned positive

NYSE:SPXC   SPX Technologies, Inc.
This is a Bullish indicator signaling SPXC's price could rise from here. Traders may explore going long the stock or buying call options. Tickeron's A.I.dvisor identified 49 similar cases where SPXC's MACD histogram became positive, and 38 of them led to successful outcomes. Odds of Success: 78%. Current price $56.34 is above $54.72 the highest support line found by Tickeron A.I. Throughout the month of 01/20/21 - 02/22/21, the price experienced a -4% Downtrend, while the week of 02/12/21 - 02/22/21 shows a +3% Uptrend.

Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on February 10, 2021. You may want to consider a long position or call options on SPXC as a result. Tickeron A.I. detected that in 63 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.

The Moving Average Convergence Divergence (MACD) for SPXC just turned positive on February 22, 2021. Looking at past instances where SPXC's MACD turned positive, the stock continued to rise in 38 of 49 cases over the following month. The odds of a continued upward trend are 78%.

SPXC moved above its 50-day Moving Average on February 19, 2021 date and that indicates a change from a downward trend to an upward trend.

The 10-day Moving Average for SPXC crossed bullishly above the 50-day moving average on February 22, 2021. This indicates that the trend has shifted higher and could be considered a buy signal. Tickeron A.I. detected that in 13 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 76%.

Following a +4.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where SPXC advanced for three days, in 248 of 329 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.